Thinly traded nano cap Akari Therapeutics (AKTX +5.9%) is up on average volume in reaction to preclinical data
on a long-acting version of lead drug nomacopan (PAS-nomacopan) that,
it says, supports its use for back-of-the-eye diseases with
less-frequent injections.
In a mouse model, PAS-nomacopan lowered
intraocular levels of VEGF as effectively as an anti-VEGF antibody (74%
and 68%, respectively) compared to saline control. It also significantly
reduced retinal inflammation versus control.
A Phase 2 study in atopic keratoconjunctivitis is ongoing. Additional preclinical work will include models of AMD.
https://seekingalpha.com/news/3534784-akari-therapeutics-up-6-on-encouraging-nomacopan-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.